{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:40:43Z","timestamp":1792190443822,"version":"4.4.0"},"reference-count":80,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,7,15]]},"abstract":"<jats:sec id=\"ab-jrv250009-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Non\u2013cystic fibrosis (CF) bronchiectasis is a chronic lung condition caused by permanent bronchial dilatation and inflammation and is characterized by daily cough, sputum, and recurrent exacerbations. Approximately 500\u202f000 people in the US have non-CF bronchiectasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250009-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Non-CF bronchiectasis may be associated with prior pneumonia, infection with nontuberculous mycobacteria or tuberculosis, genetic conditions (eg, \u03b1\n                      <jats:sub>1<\/jats:sub>\n                      -antitrypsin deficiency, primary ciliary dyskinesia), autoimmune diseases (eg, rheumatoid arthritis, inflammatory bowel disease), allergic bronchopulmonary aspergillosis, and immunodeficiency syndromes (eg, common variable immunodeficiency). Up to 38% of cases are idiopathic. According to US data, conditions associated with non-CF bronchiectasis include gastroesophageal reflux disease (47%), asthma (29%), and chronic obstructive pulmonary disease (20%). The prevalence of non-CF bronchiectasis increases substantially with age (7 per 100\u202f000 in individuals 18-34 years vs 812 per 100\u202f000 in those \u226575 years) and is more common in women than men (180 vs 95 per 100\u202f000). Diagnosis is confirmed with noncontrast chest computed tomography showing dilated airways and often airway thickening and mucus plugging. Initial diagnostic evaluation involves blood testing (complete blood cell count with differential); immunoglobulin quantification testing (IgG, IgA, IgE, and IgM); sputum cultures for bacteria, mycobacteria, and fungi; and prebronchodilator and postbronchodilator spirometry. Treatment includes airway clearance techniques; nebulization of saline to loosen tenacious secretions; and regular exercise, participation in pulmonary rehabilitation, or both. Inhaled bronchodilators (\u03b2-agonists and antimuscarinic agents) and inhaled corticosteroids are indicated for patients with bronchiectasis who have asthma or chronic obstructive pulmonary disease. Exacerbations of bronchiectasis, which typically present with increased cough and sputum and worsened fatigue, are associated with progressive decline in lung function and decreased quality of life. Exacerbations should be treated with oral or intravenous antibiotics. Individuals with 3 or more exacerbations of bronchiectasis annually may benefit from long-term inhaled antibiotics (eg, colistin, gentamicin) or daily oral macrolides (eg, azithromycin). Lung transplant may be considered for patients with severely impaired pulmonary function, frequent exacerbations, or both. Among patients with non-CF bronchiectasis, mortality is higher for those with frequent and severe exacerbations, infection with\n                      <jats:italic>Pseudomonas aeruginosa,<\/jats:italic>\n                      and comorbidities, such as chronic obstructive pulmonary disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250009-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Non-CF bronchiectasis is a chronic lung condition that typically causes chronic cough and daily sputum production. Exacerbations are associated with progressive decline in lung function and decreased quality of life. Management involves treatment of conditions associated with bronchiectasis, airway clearance techniques, oral or intravenous antibiotics for acute exacerbations, and consideration of long-term inhaled antibiotics or oral macrolides for patients with 3 or more exacerbations annually.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.2680","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:31:42Z","timestamp":1745839902000},"page":"253","source":"Crossref","is-referenced-by-count":49,"title":["Non\u2013Cystic Fibrosis Bronchiectasis in Adults"],"prefix":"10.1001","volume":"334","author":[{"given":"Alan F.","family":"Barker","sequence":"first","affiliation":[{"name":"Pulmonary, Allergy and Critical Care, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Karamooz","sequence":"additional","affiliation":[{"name":"Pulmonary, Allergy and Critical Care, Oregon Health & Science University, Portland"},{"name":"Pulmonary and Critical Care, Portland VA Health Care System, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"21","key":"jrv250009r1","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review.","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"jrv250009r2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01504-2023","article-title":"Diagnostic delay and access to care in bronchiectasis: data from the EMBARC\/ELF patient survey.","volume":"64","author":"Spinou","year":"2024","journal-title":"Eur Respir J"},{"issue":"4","key":"jrv250009r3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/resp.14479","article-title":"Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand.","volume":"28","author":"Chang","year":"2023","journal-title":"Respirology"},{"key":"jrv250009r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society guideline for bronchiectasis in adults.","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"issue":"3","key":"jrv250009r5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis.","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"10150","key":"jrv250009r6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"jrv250009r7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMra2202819","article-title":"Bronchiectasis\u2014a clinical review.","volume":"387","author":"O\u2019Donnell","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv250009r8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21037\/atm-22-3437","article-title":"Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention.","volume":"11","author":"Choi","year":"2023","journal-title":"Ann Transl Med"},{"issue":"168","key":"jrv250009r9","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0015-2023","article-title":"Basic, translational and clinical aspects of bronchiectasis in adults.","volume":"32","author":"Chalmers","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"6","key":"jrv250009r10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.chest.2018.07.014","article-title":"Characteristics and health-care utilization history of patients with bronchiectasis in US Medicare enrollees with prescription drug plans, 2006 to 2014.","volume":"154","author":"Henkle","year":"2018","journal-title":"Chest"},{"issue":"4","key":"jrv250009r11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013.","volume":"14","author":"Weycker","year":"2017","journal-title":"Chron Respir Dis"},{"issue":"1","key":"jrv250009r12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.","volume":"47","author":"Quint","year":"2016","journal-title":"Eur Respir J"},{"issue":"6","key":"jrv250009r13","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1183\/13993003.00954-2015","article-title":"Bronchiectasis in Germany: a population-based estimation of disease prevalence.","volume":"46","author":"Ringshausen","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"jrv250009r14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1513\/AnnalsATS.201511-740PS","article-title":"Bronchiectasis in China.","volume":"13","author":"Lin","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"173","key":"jrv250009r15","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0096-2024","article-title":"Bronchiectasis in Asia: a review of current status and challenges.","volume":"33","author":"Choi","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"5","key":"jrv250009r16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry.","volume":"151","author":"Aksamit","year":"2017","journal-title":"Chest"},{"issue":"7","key":"jrv250009r17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","article-title":"Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis Registry (EMBARC).","volume":"11","author":"Chalmers","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"18","key":"jrv250009r18","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.3390\/jcm12185782","article-title":"Etiology of bronchiectasis in the world: data from the published national and international registries.","volume":"12","author":"G\u00f3mez-Olivas","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"jrv250009r19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"Eur Respir J"},{"issue":"8","key":"jrv250009r20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1513\/AnnalsATS.202108-965OC","article-title":"Staphylococcus aureus in non\u2013cystic fibrosis bronchiectasis: prevalence and genomic basis of high inoculum \u00df-lactam resistance.","volume":"19","author":"Mossman","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"jrv250009r21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.chest.2023.06.014","article-title":"Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis.","volume":"164","author":"Loebinger","year":"2023","journal-title":"Chest"},{"issue":"5","key":"jrv250009r22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.resinv.2022.06.002","article-title":"The role of viral infections in pulmonary exacerbations of patients with non\u2013cystic fibrosis bronchiectasis: a systematic review.","volume":"60","author":"Kartsiouni","year":"2022","journal-title":"Respir Investig"},{"key":"jrv250009r23","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/642503","article-title":"Neutrophilic bronchial inflammation correlates with clinical and functional findings in patients with noncystic fibrosis bronchiectasis.","volume":"2015","author":"Dente","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"7","key":"jrv250009r24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1164\/rccm.201712-2423OC","article-title":"Blood neutrophils are reprogrammed in bronchiectasis.","volume":"198","author":"Bedi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv250009r25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12931-017-0691-x","article-title":"Neutrophil elastase in bronchiectasis.","volume":"18","author":"Gramegna","year":"2017","journal-title":"Respir Res"},{"issue":"8","key":"jrv250009r26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study.","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"6","key":"jrv250009r27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01702-2020","article-title":"Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study.","volume":"56","author":"Gramegna","year":"2020","journal-title":"Eur Respir J"},{"issue":"11","key":"jrv250009r28","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1164\/rccm.202303-0499OC","article-title":"Inflammatory molecular endotypes in bronchiectasis: a European multicenter cohort study.","volume":"208","author":"Choi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"jrv250009r29","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterization of eosinophilic bronchiectasis: a European multicohort study.","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"jrv250009r30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1164\/rccm.201906-1219OC","article-title":"Airway mucus hyperconcentration in non\u2013cystic fibrosis bronchiectasis.","volume":"201","author":"Ramsey","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"jrv250009r31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1164\/rccm.202306-1093OC","article-title":"Proximal and distal bronchioles contribute to the pathogenesis of non\u2013cystic fibrosis bronchiectasis.","volume":"209","author":"Asakura","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"jrv250009r32","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","article-title":"Physiology and pathophysiology of human airway mucus.","volume":"102","author":"Hill","year":"2022","journal-title":"Physiol Rev"},{"issue":"2","key":"jrv250009r33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01966-2023","article-title":"Airway IL-1\u00df is related to disease severity and mucociliary function in bronchiectasis.","volume":"64","author":"Perea","year":"2024","journal-title":"Eur Respir J"},{"issue":"699","key":"jrv250009r34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo7728","article-title":"Chronic airway epithelial hypoxia exacerbates injury in muco-obstructive lung disease through mucus hyperconcentration.","volume":"15","author":"Mikami","year":"2023","journal-title":"Sci Transl Med"},{"issue":"4","key":"jrv250009r35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1164\/rccm.202312-2275ED","article-title":"Small airways in non\u2013cystic fibrosis bronchiectasis.","volume":"209","author":"Dickinson","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"jrv250009r36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.","volume":"10","author":"Aliberti","year":"2022","journal-title":"Lancet Respir Med"},{"key":"jrv250009r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101812","article-title":"Bronchiectasis and cough: an old relationship in need of renewed attention.","volume":"57","author":"Mac Aog\u00e1in","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"jrv250009r38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01554-2023","article-title":"Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).","volume":"63","author":"Aliberti","year":"2024","journal-title":"Eur Respir J"},{"issue":"12","key":"jrv250009r39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non\u2013cystic fibrosis bronchiectasis: the BAT randomized controlled trial.","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"156","key":"jrv250009r40","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0120-2019","article-title":"The radiological diagnosis of bronchiectasis: what\u2019s in a name?","volume":"29","author":"Tiddens","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"173","key":"jrv250009r41","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0234-2023","article-title":"Biomarkers in bronchiectasis.","volume":"33","author":"Johnson","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"1","key":"jrv250009r42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","article-title":"Clinical picture and treatment of 2212 patients with common variable immunodeficiency.","volume":"134","author":"Gathmann","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"jrv250009r43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ppul.24599","article-title":"Bronchiectasis in common variable immunodeficiency: a systematic review and meta-analysis.","volume":"55","author":"Ramzi","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"jrv250009r44","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline.","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"jrv250009r45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.rmed.2018.10.031","article-title":"A comprehensive approach to lung function in bronchiectasis.","volume":"145","author":"Radovanovic","year":"2018","journal-title":"Respir Med"},{"issue":"6","key":"jrv250009r46","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.","volume":"49","author":"Hill","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"jrv250009r47","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis.","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv250009r48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.chest.2019.07.012","article-title":"Managing massive hemoptysis.","volume":"157","author":"Davidson","year":"2020","journal-title":"Chest"},{"issue":"4","key":"jrv250009r49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5152\/dir.2017.16454","article-title":"Bronchial artery embolization in hemoptysis: a systematic review.","volume":"23","author":"Panda","year":"2017","journal-title":"Diagn Interv Radiol"},{"issue":"1","key":"jrv250009r50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ccm.2021.12.002","article-title":"Allergic bronchopulmonary aspergillosis.","volume":"43","author":"Agarwal","year":"2022","journal-title":"Clin Chest Med"},{"key":"jrv250009r51","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.rmed.2018.06.031","article-title":"A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: current understanding and future risk.","volume":"141","author":"McDonnell","year":"2018","journal-title":"Respir Med"},{"issue":"1","key":"jrv250009r52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02053-2022","article-title":"European Respiratory Society statement on airway clearance techniques in adults with bronchiectasis.","volume":"62","author":"Herrero-Cortina","year":"2023","journal-title":"Eur Respir J"},{"issue":"4","key":"jrv250009r53","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.chest.2020.06.050","article-title":"Airway clearance techniques in bronchiectasis: analysis from the United States Bronchiectasis and Non-TB Mycobacteria Research Registry.","volume":"158","author":"Basavaraj","year":"2020","journal-title":"Chest"},{"issue":"6","key":"jrv250009r54","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01689-2023","article-title":"Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).","volume":"63","author":"Spinou","year":"2024","journal-title":"Eur Respir J"},{"issue":"6","key":"jrv250009r55","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/resp.13047","article-title":"Mucoactive agents for chronic, non\u2013cystic fibrosis lung disease: a systematic review and meta-analysis.","volume":"22","author":"Tarrant","year":"2017","journal-title":"Respirology"},{"issue":"12","key":"jrv250009r56","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.rmed.2011.07.019","article-title":"Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis.","volume":"105","author":"Kellett","year":"2011","journal-title":"Respir Med"},{"issue":"5","key":"jrv250009r57","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.rmed.2011.12.021","article-title":"The long term effect of inhaled hypertonic saline 6% in non\u2013cystic fibrosis bronchiectasis.","volume":"106","author":"Nicolson","year":"2012","journal-title":"Respir Med"},{"issue":"6","key":"jrv250009r58","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02184-2021","article-title":"Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial.","volume":"59","author":"Jayaram","year":"2022","journal-title":"Eur Respir J"},{"issue":"5","key":"jrv250009r59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000996.pub3","article-title":"Inhaled corticosteroids for bronchiectasis.","volume":"5","author":"Kapur","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"jrv250009r60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010327.pub2","article-title":"Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis.","volume":"2014","author":"Goyal","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"jrv250009r61","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00453-2020","article-title":"Blood eosinophils predict inhaled fluticasone response in bronchiectasis.","volume":"56","author":"Aliberti","year":"2020","journal-title":"Eur Respir J"},{"issue":"4","key":"jrv250009r62","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.apmr.2016.05.017","article-title":"Pulmonary rehabilitation in individuals with non\u2013cystic fibrosis bronchiectasis: a systematic review.","volume":"98","author":"Lee","year":"2017","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"jrv250009r63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1465-9921-15-44","article-title":"The short and long term effects of exercise training in non\u2013cystic fibrosis bronchiectasis\u2014a randomised controlled trial.","volume":"15","author":"Lee","year":"2014","journal-title":"Respir Res"},{"key":"jrv250009r64","doi-asserted-by":"publisher","DOI":"10.1177\/1479972318790269","article-title":"Azithromycin or erythromycin? macrolides for non\u2013cystic fibrosis bronchiectasis in adults: a systematic review and adjusted indirect treatment comparison.","volume":"16","author":"Li","year":"2019","journal-title":"Chron Respir Dis"},{"issue":"5","key":"jrv250009r65","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/00325481.2017.1285677","article-title":"Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician.","volume":"129","author":"Cramer","year":"2017","journal-title":"Postgrad Med"},{"issue":"3","key":"jrv250009r66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012406.pub2","article-title":"Macrolide antibiotics for bronchiectasis.","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv250009r67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chest.2024.01.045","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis.","volume":"166","author":"Cordeiro","year":"2024","journal-title":"Chest"},{"issue":"10","key":"jrv250009r68","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S2213-2600(24)00225-X","article-title":"Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.","volume":"12","author":"Haworth","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"3","key":"jrv250009r69","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-0038-1660472","article-title":"Treatment of Mycobacterium avium complex (MAC).","volume":"39","author":"Griffith","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"jrv250009r70","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.chest.2023.12.006","article-title":"Tolerability outcomes of American Thoracic Society\/Infectious Diseases Society of America guideline-recommended multidrug antibiotic treatment for Mycobacterium avium complex pulmonary disease in US Medicare beneficiaries with bronchiectasis.","volume":"165","author":"Ku","year":"2024","journal-title":"Chest"},{"issue":"1","key":"jrv250009r71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.chest.2023.02.015","article-title":"Patient-reported symptom and health-related quality-of-life validation and responsiveness during the first 6 months of treatment for Mycobacterium avium complex pulmonary disease.","volume":"164","author":"Henkle","year":"2023","journal-title":"Chest"},{"issue":"1","key":"jrv250009r72","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1164\/rccm.202307-1165OC","article-title":"Five-year outcomes among US Bronchiectasis and NTM Research Registry patients.","volume":"210","author":"Aksamit","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"jrv250009r73","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.athoracsur.2014.04.049","article-title":"Lung resection improves the quality of life of patients with symptomatic bronchiectasis.","volume":"98","author":"Vallilo","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"jrv250009r74","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00607-2021","article-title":"Outcomes and survival following lung transplantation in non\u2013cystic fibrosis bronchiectasis.","volume":"8","author":"Jung","year":"2022","journal-title":"ERJ Open Res"},{"issue":"2","key":"jrv250009r75","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.rmed.2013.12.015","article-title":"Mortality in non\u2013cystic fibrosis bronchiectasis: a prospective cohort analysis.","volume":"108","author":"Goeminne","year":"2014","journal-title":"Respir Med"},{"issue":"1","key":"jrv250009r76","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1164\/rccm.202309-1614OC","article-title":"The association between bronchiectasis and chronic obstructive pulmonary disease: data from the European Bronchiectasis Registry (EMBARC).","volume":"210","author":"Polverino","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"jrv250009r77","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2213-2600(16)30320-4","article-title":"Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.","volume":"4","author":"McDonnell","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"jrv250009r78","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1038\/s41598-021-86407-8","article-title":"Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities.","volume":"11","author":"Choi","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"jrv250009r79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.34197\/ats-scholar.2022-0061IN","article-title":"Pilot evaluation of a management toolkit for airway clearance therapy in bronchiectasis (IMPACT BE).","volume":"4","author":"Solomon","year":"2023","journal-title":"ATS Sch"},{"key":"jrv250009r80","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12913-015-1004-z","article-title":"Defining the content and delivery of an intervention to Change Adherence to Treatment in Bonchiectasis [sic] (CAN-BE): a qualitative approach incorporating the theoretical domains framework, behavioural change techniques and stakeholder expert panels.","volume":"15","author":"McCullough","year":"2015","journal-title":"BMC Health Serv Res"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2833340\/jama_barker_2025_rv_250009_1751578558.12505.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:01:20Z","timestamp":1752591680000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2833340"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7,15]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.2680","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}